European Journal of Radiology
Volume 51, Supplement , Pages S19-S23, June 2004

Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound

Department of Radiology, General Hospital, P. le Solaro 3, 21052 Busto Arsizio, VA, Italy

Received 1 March 2004; received in revised form 8 March 2004; accepted 15 March 2004.

Abstract 

Radiofrequency (RF) treatments of non-resectable hepatic tumors are generally guided with real-time sonography, which, however, cannot differentiate necrotic changes from viable tumor. To achieve complete treatment of hepatic tumors, accurate imaging techniques are needed for close treatment follow-up. Usually contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are used; however, they can be performed only at the end of treatment sessions. In this field, contrast-enhanced ultrasound (CEUS) has shown to improve the sensitivity of plain ultrasonography. Recently, further developments of contrast-enhanced US technique have significantly increased its clinical utility. Continuous mode, low MI scans performed with harmonic imaging and contrast specific software appears as a very useful technique for the visualization of both macro- and microcirculation with depiction of tumor vascularisation.

In our hospital, we have been employing contrast-enhanced sonography with sulphur hexaflouride microbubbles (SonoVue®, Bracco, Italy) before, during and immediately at the end of RF ablation procedures to monitor and assess the therapeutic result prior to closing the treatment session. The results obtained in a group of 109 patients with hepatocellular carcinoma (HCC) in liver cirrhosis (192 lesions) and in 53 patients with liver metastases (97 lesions) undergoing a single session of percutaneous RF tumor ablation, showed that the sensitivity of CEUS for the detection of residual tumor was almost equivalent to that of contrast-enhanced helical CT. More importantly, since the introduction of intraoperative CEUS the rate of partially unablated tumors has dropped from 16.1 to 5.9%. Cost-effectiveness and reduction of patients’ discomfort related to the need of re-treatment are the two most outstanding advantages of CEUS in this field.

Keywords: Radiofrequency tumor ablation, Contrast-enhanced ultrasound, Liver, HCC, Metastases

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0720-048X(04)00125-1

doi:10.1016/j.ejrad.2004.03.035

European Journal of Radiology
Volume 51, Supplement , Pages S19-S23, June 2004